Literature DB >> 10896923

Mechanisms of endotoxin tolerance in patients with alcoholic liver cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor receptors as well as effector cell desensitisation.

V von Baehr1, W D Döcke, M Plauth, C Liebenthal, S Küpferling, H Lochs, R Baumgarten, H D Volk.   

Abstract

BACKGROUND: In patients with alcoholic liver cirrhosis, endotoxaemia is a frequent finding. Unknown mechanisms, however, prevent typical clinical symptoms of endotoxaemia in many patients.
METHODS: We determined plasma levels of pro- and anti-inflammatory mediators, ex vivo cytokine secretion capacity, and expression of tumour necrosis factor (TNF) receptors on phagocytic blood cells in 49 patients with alcoholic cirrhosis and 41 age matched healthy controls.
RESULTS: In addition to increased levels of proinflammatory cytokines in cirrhotic patients, we observed consistent upregulation of the anti-inflammatory mediators interleukin 10 (IL-10) (plasma 15.75 (1. 6) v 6.6 (1.3) pg/ml (p<0.001); ex-vivo 108.4 (22.0) v 40.1 (7.4) pg/ml (p<0.05)), interleukin 1 receptor antagonist (plasma 527.1 (83) v 331.4 (56) pg/ml (p<0.05); ex vivo 19.9 (3.4) v 10.2 (2.7) ng/ml (p<0.01)), and soluble TNF receptors (sTNF-R) in plasma (sTNF-RI 3157.2 (506.2) v 607.9 (300.3) pg/ml; sTNF-RII 3331.0 (506. 2) v 1066.4 (225.1) pg/ml (p<0.001 for both)). Desensitisation at the target cell level was indicated by reduced expression of TNF receptor I on granulocytes (64.8 (6.5) v 40.1 (7.3)% positive cells; p<0.05) and unaltered plasma levels of soluble E-selectin.
CONCLUSION: In patients with alcoholic liver cirrhosis, upregulation of the pro- and anti-inflammatory cytokine system and simultaneous desensitisation of effector cells could explain the restricted systemic inflammatory response to chronic endotoxaemia. This alteration in immune status may lead to impairment of host defences against infections which are frequent complications of alcoholic cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896923      PMCID: PMC1728013          DOI: 10.1136/gut.47.2.281

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  Qualitative and quantitative relationships of the fecal flora in cirrhotic patients with portal systemic encephalopathy and following portacaval anastomosis.

Authors:  M H Floch; J Katz; H O Conn
Journal:  Gastroenterology       Date:  1970-07       Impact factor: 22.682

2.  Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis.

Authors:  A B Lumsden; J M Henderson; M H Kutner
Journal:  Hepatology       Date:  1988 Mar-Apr       Impact factor: 17.425

Review 3.  The role of endotoxin in liver injury.

Authors:  J P Nolan
Journal:  Gastroenterology       Date:  1975-12       Impact factor: 22.682

4.  Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis.

Authors:  I A Rajkovic; R Williams
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

5.  High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production.

Authors:  J Deviere; J Content; C Denys; P Vandenbussche; L Schandene; J Wybran; E Dupont
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

6.  Soluble E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; J H Levy; M L Petroni; A C Douds; J D Maxwell; T C Northfield
Journal:  J Hepatol       Date:  1995-04       Impact factor: 25.083

7.  Increased plasma tumor necrosis factor in severe alcoholic hepatitis.

Authors:  G L Bird; N Sheron; A K Goka; G J Alexander; R S Williams
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

8.  Morphologic changes in the small intestine after chronic alcohol consumption.

Authors:  J Persson; N O Berg; K Sjölund; R Stenling; P H Magnusson
Journal:  Scand J Gastroenterol       Date:  1990-02       Impact factor: 2.423

9.  Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1.

Authors:  D Wallach; H Holtmann; H Engelmann; Y Nophar
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

10.  Portal and systemic bacteraemia and endotoxaemia in liver disease.

Authors:  D R Triger; T D Boyer; J Levin
Journal:  Gut       Date:  1978-10       Impact factor: 23.059

View more
  21 in total

Review 1.  Gut flora and bacterial translocation in chronic liver disease.

Authors:  John Almeida; Sumedha Galhenage; Jennifer Yu; Jelica Kurtovic; Stephen M Riordan
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

2.  ABCA1 promotes the efflux of bacterial LPS from macrophages and accelerates recovery from LPS-induced tolerance.

Authors:  Patricia A Thompson; Karine C Gauthier; Alan W Varley; Richard L Kitchens
Journal:  J Lipid Res       Date:  2010-05-15       Impact factor: 5.922

3.  The bile duct ligated rat: A relevant model to study muscle mass loss in cirrhosis.

Authors:  Cristina R Bosoi; Mariana M Oliveira; Rafael Ochoa-Sanchez; Mélanie Tremblay; Gabriella A Ten Have; Nicolaas E Deutz; Christopher F Rose; Chantal Bemeur
Journal:  Metab Brain Dis       Date:  2016-12-15       Impact factor: 3.584

Review 4.  Alcoholic hepatitis and HCV interactions in the modulation of liver disease.

Authors:  C S Punzalan; T N Bukong; G Szabo
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

Review 5.  The role of the liver in sepsis.

Authors:  Jun Yan; Song Li; Shulin Li
Journal:  Int Rev Immunol       Date:  2014-03-10       Impact factor: 5.311

6.  Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease.

Authors:  Valentina Medici; Janet M Peerson; Sally P Stabler; Samuel W French; Jesse F Gregory; Maria Catrina Virata; Antony Albanese; Christopher L Bowlus; Sridevi Devaraj; Edward A Panacek; Nazir Rahim; John R Richards; Lorenzo Rossaro; Charles H Halsted
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

7.  Expression of lipopolysaccharide binding protein and its receptor CD14 in experimental alcoholic liver disease.

Authors:  G Q Zuo; J P Gong; C A Liu; S W Li; X C Wu; K Yang; Y Li
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

8.  Cytokine production in patients with cirrhosis and TLR4 polymorphisms.

Authors:  Juan Camilo Nieto; Elisabet Sánchez; Eva Román; Silvia Vidal; Laia Oliva; Carlos Guarner-Argente; Maria Poca; Xavier Torras; Cándido Juárez; Carlos Guarner; German Soriano
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

9.  Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation.

Authors:  B Massonnet; A Delwail; J-M Ayrault; C Chagneau-Derrode; J-C Lecron; C Silvain
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

10.  Host inactivation of bacterial lipopolysaccharide prevents prolonged tolerance following gram-negative bacterial infection.

Authors:  Mingfang Lu; Alan W Varley; Shoichiro Ohta; John Hardwick; Robert S Munford
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.